These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36933622)

  • 1. AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Moosavi Baigi F
    Toxicol Appl Pharmacol; 2023 May; 466():116470. PubMed ID: 36933622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
    Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
    Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
    Amiri Darban S; Nikoofal-Sahlabadi S; Amiri N; Kiamanesh N; Mehrabian A; Zendehbad B; Gholizadeh Z; Jaafari MR
    Colloids Surf B Biointerfaces; 2018 Apr; 164():107-115. PubMed ID: 29413587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
    Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M
    Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
    Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
    J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma.
    Rastgoo M; Hosseinzadeh H; Alavizadeh H; Abbasi A; Ayati Z; Jaafari MR
    Planta Med; 2013 Apr; 79(6):447-51. PubMed ID: 23539350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
    Amin M; Badiee A; Jaafari MR
    Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells.
    Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Banciu M; Porfire A
    Pharmacol Rep; 2018 Apr; 70(2):331-339. PubMed ID: 29477042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor.
    Shakib Z; Mahmoudi A; Moosavian SA; Malaekeh-Nikouei B
    Drug Dev Ind Pharm; 2022 Feb; 48(2):69-78. PubMed ID: 35758194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil
    Aldughaim MS; Muthana M; Alsaffar F; Barker MD
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33379361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment.
    Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Porav S; Banciu M; Porfire A
    Drug Deliv Transl Res; 2019 Feb; 9(1):260-272. PubMed ID: 30421392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
    Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
    IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.